XML 46 R28.htm IDEA: XBRL DOCUMENT
v3.25.3

REVENUE RECOGNITION AND RELATED ALLOWANCES (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Revenue from Contract with Customer [Abstract] |
Schedule of disaggregation of revenue and revenue recognized | All revenue recognized in the accompanying unaudited condensed consolidated statements of operations is considered to be revenue from contracts with customers. The following table depicts the disaggregation of revenue:
|  | Three Months Ended September 30, |  | Nine Months Ended September 30,
Products and Services (in thousands) |  | 2025 |  | 2024 |  | 2025 |  | 2024
Rare Disease and Brands |  |  |  |  |  |  |  |
Cortrophin Gel |  | $ | 101,850 |  |  | $ | 52,555 |  |  | $ | 236,347 |  |  | $ | 138,685 |
ILUVIEN and YUTIQ |  | 16,600 |  |  | 3,871 |  |  | 55,025 |  |  | 3,871 |
Rare Disease total net revenues |  | $ | 118,450 |  |  | $ | 56,426 |  |  | $ | 291,372 |  |  | $ | 142,556 |
Brands |  | 10,675 |  |  | 9,195 |  |  | 48,993 |  |  | 44,900 |
Rare Disease and Brands total net revenues |  | $ | 129,125 |  |  | $ | 65,621 |  |  | $ | 340,365 |  |  | $ | 187,456 |
Generics and Other |  |  |  |  |  |  |  |
Generic pharmaceutical products |  | $ | 94,375 |  |  | $ | 78,223 |  |  | $ | 283,350 |  |  | $ | 222,404 |
Royalties and other pharmaceutical services |  | 4,313 |  |  | 4,488 |  |  | 12,591 |  |  | 13,942 |
Generics and Other total net revenues |  | 98,688 |  |  | 82,711 |  |  | 295,941 |  |  | 236,346 |
Total net revenues |  | $ | 227,813 |  |  | $ | 148,332 |  |  | $ | 636,306 |  |  | $ | 423,802 |
Schedule of accruals and allowances | The following table summarizes activity in the unaudited condensed consolidated balance sheets for accruals and allowances for the nine months ended September 30, 2025 and 2024, respectively:
| Accruals for Chargebacks, Returns, and Other Allowances
(in thousands) | Chargebacks |  | Government Rebates |  | Returns |  | Administrative Fees and Other Rebates |  | Prompt Payment Discounts
Balance at December 31, 2023 | $ | 84,208 |  |  | $ | 12,168 |  |  | $ | 29,678 |  |  | $ | 11,412 |  |  | $ | 4,865 |
Impact of Alimera acquisition | 95 |  |  | — |  |  | 3,095 |  |  | 671 |  |  | — |
Accruals/Adjustments | 403,201 |  |  | 19,757 |  |  | 28,737 |  |  | 44,622 |  |  | 17,159 |
Credits Taken Against Reserve | (410,508) |  |  | (21,232) |  |  | (24,442) |  |  | (43,486) |  |  | (17,218) |
Balance at September 30, 2024 (1) | $ | 76,996 |  |  | $ | 10,693 |  |  | $ | 37,068 |  |  | $ | 13,219 |  |  | $ | 4,806 |
Balance at December 31, 2024 | $ | 105,630 |  |  | $ | 18,714 |  |  | $ | 39,274 |  |  | $ | 19,588 |  |  | $ | 6,258 |
Accruals/Adjustments | 493,008 |  |  | 53,983 |  |  | 30,977 |  |  | 62,159 |  |  | 26,199 |
Credits Taken Against Reserve | (496,765) |  |  | (35,665) |  |  | (20,246) |  |  | (58,645) |  |  | (25,495) |
Balance at September 30, 2025 (1) | $ | 101,873 |  |  | $ | 37,032 |  |  | $ | 50,005 |  |  | $ | 23,102 |  |  | $ | 6,962 |
______________________________________________ (1)Chargebacks are included as an offset to accounts receivable, net of chargebacks and other allowances in the unaudited condensed consolidated balance sheets. Administrative Fees and Other Rebates and Prompt Payment Discounts are included as a reduction to accounts receivable, net of chargebacks and other allowances or accrued expenses and other in the unaudited condensed consolidated balance sheets. Returns are included in returned goods reserve in the unaudited condensed consolidated balance sheets. Government Rebates are included in accrued government rebates in the unaudited condensed consolidated balance sheets.
Schedule of customer concentration | The four customers represent the total percentage of net revenues as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Customer 1 | 13 | % |  | 20 | % |  | 19 | % |  | 26 | %
Customer 2 | 7 | % |  | 10 | % |  | 9 | % |  | 12 | %
Customer 3 | 17 | % |  | 14 | % |  | 14 | % |  | 12 | %
Customer 4 | 26 | % |  | 17 | % |  | 21 | % |  | 15 | %

X
- Definition Schedule Of Valuation And Qualifying Accounts Disclosure + References No definition available. + Details
Name: | anip_ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock
Namespace Prefix: | anip_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 275 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 275 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration